NY-ESO-1 expression and immunogenicity in esophageal cancer

Shoichiro Fujita, Hisashi Wada, Achim A. Jungbluth, Shuichiro Sato, Tetsuya Nakata, Yuji Noguchi, Yuichiro Doki, Masayoshi Yasui, Yurika Sugita, Takushi Yasuda, Masahiko Yano, Toshiro Ono, Yao Tseng Chen, Masahiko Higashiyama, Sacha Gnjatic, Lloyd J. Old, Eiichi Nakayama, Morito Monden

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: Although NY-ESO-1 was isolated from an esophageal carcinoma patient, its expression in this type of cancer and its immunogenicity in esophageal cancer patients have not yet been fully elucidated. We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients. Experimental Design: One hundred twenty three esophageal squamous cell carcinoma specimens were analyzed for the expression of NY-ESO-1 mRNA by conventional and real-time reverse transcription-PCR and the expression of protein by immunohistochemistry and Western blot. Sera and peripheral blood lymphocytes from 51 patients were analyzed for the NY-ESO-1 antibody production by enzyme-linked immunosorbent assay and NY-ESO-1 T cell response by enzyme-linked immunospot assay. Survival analyses were also performed. Results: NY-ESO-1 mRNA was expressed in 41 of 123 (33%) esophageal squamous cell carcinoma specimens, and its expression was found at higher frequency in well-differentiated and moderately differentiated type of cancer. No mRNA copy was detected in any of the adjacent normal tissues. Twenty-one of 24 (87.5%) NY-ESO-1 mRNA-positive tumors were stained positively by immunohistochemistry. Correlation between the level of NY-ESO-1 mRNA expression and the degree of immunohistochemistry positivity was observed. Antibody production was observed in 2 patients with famers that showed protein expression. Furthermore, a CD8 T-cell response against NY-ESO-1 was observed in 1 of the 2 seropositive patients. Conclusions: The high expression frequency of NY-ESO-1 mRNA and protein indicates NY-ESO-1 as a feasible vaccine target in esophageal cancer.

Original languageEnglish
Pages (from-to)6551-6558
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number19
DOIs
Publication statusPublished - Oct 1 2004

Fingerprint

Esophageal Neoplasms
Messenger RNA
Immunohistochemistry
Antibody Formation
Proteins
T-Lymphocytes
Enzyme-Linked Immunospot Assay
Neoplasms
Survival Analysis
Reverse Transcription
Research Design
Vaccines
Western Blotting
Enzyme-Linked Immunosorbent Assay
Lymphocytes
Carcinoma
Polymerase Chain Reaction
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fujita, S., Wada, H., Jungbluth, A. A., Sato, S., Nakata, T., Noguchi, Y., ... Monden, M. (2004). NY-ESO-1 expression and immunogenicity in esophageal cancer. Clinical Cancer Research, 10(19), 6551-6558. https://doi.org/10.1158/1078-0432.CCR-04-0819

NY-ESO-1 expression and immunogenicity in esophageal cancer. / Fujita, Shoichiro; Wada, Hisashi; Jungbluth, Achim A.; Sato, Shuichiro; Nakata, Tetsuya; Noguchi, Yuji; Doki, Yuichiro; Yasui, Masayoshi; Sugita, Yurika; Yasuda, Takushi; Yano, Masahiko; Ono, Toshiro; Chen, Yao Tseng; Higashiyama, Masahiko; Gnjatic, Sacha; Old, Lloyd J.; Nakayama, Eiichi; Monden, Morito.

In: Clinical Cancer Research, Vol. 10, No. 19, 01.10.2004, p. 6551-6558.

Research output: Contribution to journalArticle

Fujita, S, Wada, H, Jungbluth, AA, Sato, S, Nakata, T, Noguchi, Y, Doki, Y, Yasui, M, Sugita, Y, Yasuda, T, Yano, M, Ono, T, Chen, YT, Higashiyama, M, Gnjatic, S, Old, LJ, Nakayama, E & Monden, M 2004, 'NY-ESO-1 expression and immunogenicity in esophageal cancer', Clinical Cancer Research, vol. 10, no. 19, pp. 6551-6558. https://doi.org/10.1158/1078-0432.CCR-04-0819
Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clinical Cancer Research. 2004 Oct 1;10(19):6551-6558. https://doi.org/10.1158/1078-0432.CCR-04-0819
Fujita, Shoichiro ; Wada, Hisashi ; Jungbluth, Achim A. ; Sato, Shuichiro ; Nakata, Tetsuya ; Noguchi, Yuji ; Doki, Yuichiro ; Yasui, Masayoshi ; Sugita, Yurika ; Yasuda, Takushi ; Yano, Masahiko ; Ono, Toshiro ; Chen, Yao Tseng ; Higashiyama, Masahiko ; Gnjatic, Sacha ; Old, Lloyd J. ; Nakayama, Eiichi ; Monden, Morito. / NY-ESO-1 expression and immunogenicity in esophageal cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 19. pp. 6551-6558.
@article{494522c1d33c499fb7dfd0da9d189373,
title = "NY-ESO-1 expression and immunogenicity in esophageal cancer",
abstract = "Purpose: Although NY-ESO-1 was isolated from an esophageal carcinoma patient, its expression in this type of cancer and its immunogenicity in esophageal cancer patients have not yet been fully elucidated. We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients. Experimental Design: One hundred twenty three esophageal squamous cell carcinoma specimens were analyzed for the expression of NY-ESO-1 mRNA by conventional and real-time reverse transcription-PCR and the expression of protein by immunohistochemistry and Western blot. Sera and peripheral blood lymphocytes from 51 patients were analyzed for the NY-ESO-1 antibody production by enzyme-linked immunosorbent assay and NY-ESO-1 T cell response by enzyme-linked immunospot assay. Survival analyses were also performed. Results: NY-ESO-1 mRNA was expressed in 41 of 123 (33{\%}) esophageal squamous cell carcinoma specimens, and its expression was found at higher frequency in well-differentiated and moderately differentiated type of cancer. No mRNA copy was detected in any of the adjacent normal tissues. Twenty-one of 24 (87.5{\%}) NY-ESO-1 mRNA-positive tumors were stained positively by immunohistochemistry. Correlation between the level of NY-ESO-1 mRNA expression and the degree of immunohistochemistry positivity was observed. Antibody production was observed in 2 patients with famers that showed protein expression. Furthermore, a CD8 T-cell response against NY-ESO-1 was observed in 1 of the 2 seropositive patients. Conclusions: The high expression frequency of NY-ESO-1 mRNA and protein indicates NY-ESO-1 as a feasible vaccine target in esophageal cancer.",
author = "Shoichiro Fujita and Hisashi Wada and Jungbluth, {Achim A.} and Shuichiro Sato and Tetsuya Nakata and Yuji Noguchi and Yuichiro Doki and Masayoshi Yasui and Yurika Sugita and Takushi Yasuda and Masahiko Yano and Toshiro Ono and Chen, {Yao Tseng} and Masahiko Higashiyama and Sacha Gnjatic and Old, {Lloyd J.} and Eiichi Nakayama and Morito Monden",
year = "2004",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0819",
language = "English",
volume = "10",
pages = "6551--6558",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - NY-ESO-1 expression and immunogenicity in esophageal cancer

AU - Fujita, Shoichiro

AU - Wada, Hisashi

AU - Jungbluth, Achim A.

AU - Sato, Shuichiro

AU - Nakata, Tetsuya

AU - Noguchi, Yuji

AU - Doki, Yuichiro

AU - Yasui, Masayoshi

AU - Sugita, Yurika

AU - Yasuda, Takushi

AU - Yano, Masahiko

AU - Ono, Toshiro

AU - Chen, Yao Tseng

AU - Higashiyama, Masahiko

AU - Gnjatic, Sacha

AU - Old, Lloyd J.

AU - Nakayama, Eiichi

AU - Monden, Morito

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Purpose: Although NY-ESO-1 was isolated from an esophageal carcinoma patient, its expression in this type of cancer and its immunogenicity in esophageal cancer patients have not yet been fully elucidated. We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients. Experimental Design: One hundred twenty three esophageal squamous cell carcinoma specimens were analyzed for the expression of NY-ESO-1 mRNA by conventional and real-time reverse transcription-PCR and the expression of protein by immunohistochemistry and Western blot. Sera and peripheral blood lymphocytes from 51 patients were analyzed for the NY-ESO-1 antibody production by enzyme-linked immunosorbent assay and NY-ESO-1 T cell response by enzyme-linked immunospot assay. Survival analyses were also performed. Results: NY-ESO-1 mRNA was expressed in 41 of 123 (33%) esophageal squamous cell carcinoma specimens, and its expression was found at higher frequency in well-differentiated and moderately differentiated type of cancer. No mRNA copy was detected in any of the adjacent normal tissues. Twenty-one of 24 (87.5%) NY-ESO-1 mRNA-positive tumors were stained positively by immunohistochemistry. Correlation between the level of NY-ESO-1 mRNA expression and the degree of immunohistochemistry positivity was observed. Antibody production was observed in 2 patients with famers that showed protein expression. Furthermore, a CD8 T-cell response against NY-ESO-1 was observed in 1 of the 2 seropositive patients. Conclusions: The high expression frequency of NY-ESO-1 mRNA and protein indicates NY-ESO-1 as a feasible vaccine target in esophageal cancer.

AB - Purpose: Although NY-ESO-1 was isolated from an esophageal carcinoma patient, its expression in this type of cancer and its immunogenicity in esophageal cancer patients have not yet been fully elucidated. We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients. Experimental Design: One hundred twenty three esophageal squamous cell carcinoma specimens were analyzed for the expression of NY-ESO-1 mRNA by conventional and real-time reverse transcription-PCR and the expression of protein by immunohistochemistry and Western blot. Sera and peripheral blood lymphocytes from 51 patients were analyzed for the NY-ESO-1 antibody production by enzyme-linked immunosorbent assay and NY-ESO-1 T cell response by enzyme-linked immunospot assay. Survival analyses were also performed. Results: NY-ESO-1 mRNA was expressed in 41 of 123 (33%) esophageal squamous cell carcinoma specimens, and its expression was found at higher frequency in well-differentiated and moderately differentiated type of cancer. No mRNA copy was detected in any of the adjacent normal tissues. Twenty-one of 24 (87.5%) NY-ESO-1 mRNA-positive tumors were stained positively by immunohistochemistry. Correlation between the level of NY-ESO-1 mRNA expression and the degree of immunohistochemistry positivity was observed. Antibody production was observed in 2 patients with famers that showed protein expression. Furthermore, a CD8 T-cell response against NY-ESO-1 was observed in 1 of the 2 seropositive patients. Conclusions: The high expression frequency of NY-ESO-1 mRNA and protein indicates NY-ESO-1 as a feasible vaccine target in esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=5144230934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5144230934&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0819

DO - 10.1158/1078-0432.CCR-04-0819

M3 - Article

VL - 10

SP - 6551

EP - 6558

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -